nach oben

Erschienen in:

01.02.2020 | Original Article

Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease

verfasst von: Yanying Liu, Yuxin Zhang, Wenjie Bian, Jiangnan Fu, Xing Sun, Da Chen, Jiali Chen, Xiaozhen Zhao, Yingni Li, Wen Zhang, Zhanguo Li

Erschienen in: Clinical Rheumatology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the therapeutic efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease (IgG4-RD).

Methods

We conducted a retrospective single-center study in 17 IgG4-RD patients admitted to Peking University People’s Hospital. Patients were given iguratimod, 25 mg, twice daily and clinical data were collected at 0, 12, and 24 weeks. The baseline treatments include prednisone, cyclophosphamide, leflunomide, mycophenolate mofetil, and methotrexate. Clinical manifestation, IgG4-RD responder index (IgG-RD RI), serological indexes, gland ultrasound findings, and adverse drug effect were recorded. IgG4-RD RI scores < 3 and declining ≥ 2 were recognized as complete response (CR); IgG4-RD RI scores declining ≥ 2 but remaining ≥ 3 were recognized as partial response (PR). If a patient’s IgG4-RD RI score was 3 at the beginning, PR was considered as a 1-point decrease after the therapy.

Results

Serum IgG4 decreased significantly from 708 (321–902) mg/dl at baseline to 446 (138–396) mg/dl at 24 weeks (P = 0.0016). IgG4-RD RI decreased significantly from 9.79 ± 3.07 at baseline to 3.57 ± 1.09 at 24 weeks (P < 0.0001). Overall, 2 (14.3%) patients achieved CR, 11 (78.6%) patients achieved PR, and 1 (7.14%) patient had no response to treatment at week 24. Serum IgG level and salivary glands major diameter also decreased significantly at week 12 and 24 after treatment.

Conclusion

Iguratimod can be a therapeutic strategy to achieve remission in relapsed or refractory IgG4-RD patients inadequately responding to corticosteroid treatment with or without other immunosuppressant treatment.

Key messages

• Iguratimod was effective for relapsed or refractory IgG4-RD patients.

• Iguratimod can improve the clinical symptoms of patients, reduce the serum IgG and IgG4 levels, and can also reduce the volume of involved glands.

Kamisawa T, Zen Y, Pillai S, Stone JH (2015) IgG4-related disease. Lancet 385(9976):1460–1471. https://doi.org/10.1016/S0140-6736(14)60720-0 CrossRefPubMed

Yadlapati S, Verheyen E, Efthimiou P (2018) IgG4-related disease: a complex under-diagnosed clinical entity. Rheumatol Int 38(2):169–177. https://doi.org/10.1007/s00296-017-3765-7 CrossRefPubMed

Khosroshahi A, Wallace ZS, Crowe JL et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67(7):1688–1699. https://doi.org/10.1002/art.39132 CrossRefPubMed

Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, Stone JH (2015) IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 67(9):2466–2475. https://doi.org/10.1002/art.39205 CrossRefPubMedPubMedCentral

Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Sumida T, Mimori T, Tanaka Y, Tsubota K, Yoshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose N, Ishigaki Y, Azumi A, Kojima M, Nakamura S, Inoue D, Research Program for Intractable Disease by Ministry of Health, Labor and Welfare (MHLW) Japan G4 team (2012) A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 22(1):1–14. https://doi.org/10.1007/s10165-011-0508-6 CrossRefPubMed

Wang L, Zhang P, Wang M et al (2018) Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther 20. https://doi.org/10.1186/s13075-018-1567-2

Yunyun F, Yu P, Panpan Z, Xia Z, Linyi P, Jiaxin Z, Li Z, Shangzhu Z, Jinjing L, di W, Yamin L, Xiaowei L, Huadan X, Xuan Z, Xiaofeng Z, Fengchun Z, Yan Z, Wen Z (2019) Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford) 58(1):52–60. https://doi.org/10.1093/rheumatology/key227 CrossRef

Yamamoto M, Nojima M, Takahashi H, Yokoyama Y, Ishigami K, Yajima H, Shimizu Y, Tabeya T, Matsui M, Suzuki C, Naishiro Y, Takano K, Himi T, Imai K, Shinomura Y (2015) Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology (Oxford) 54(1):45–49. https://doi.org/10.1093/rheumatology/keu228 CrossRef

Majumder S, Mohapatra S, Lennon RJ, Piovezani Ramos G, Postier N, Gleeson FC, Levy MJ, Pearson RK, Petersen BT, Vege SS, Chari ST, Topazian MD, Witzig TE (2018) Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease. Clin Gastroenterol Hepatol 16(12):1947–1953. https://doi.org/10.1016/j.cgh.2018.02.049 CrossRefPubMed

10.

Lee HW, Moon S-H, Kim M-H, Cho DH, Jun JH, Nam K, Song TJ, Park DH, Lee SS, Seo DW, Lee SK (2018) Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. J Gastroenterol 53(8):967–977. https://doi.org/10.1007/s00535-018-1434-6 CrossRefPubMed

11.

Ye Y, Liu M, Tang L et al (2019) Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. Arthritis Res Ther 21. https://doi.org/10.1186/s13075-019-1874-2

12.

Tanaka K, Yamaguchi T, Hara M (2015) Iguratimod for the treatment of rheumatoid arthritis in Japan. Expert Rev Clin Immunol 11(5):565–573. https://doi.org/10.1586/1744666X.2015.1027151 CrossRefPubMed

13.

Li G, Yamasaki R, Fang M, Masaki K, Ochi H, Matsushita T, Kira JI (2018) Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Sci Rep 8(1):1933. https://doi.org/10.1038/s41598-018-20390-5 CrossRefPubMedPubMedCentral

14.

Ishikawa K, Ishikawa J (2019) Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients. Mod Rheumatol 29(3):418–429. https://doi.org/10.1080/14397595.2018.1481565 CrossRefPubMed

15.

Luo Q, Sun Y, Liu W et al (2013) A novel disease-modifying Antirheumatic drug, Iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and Leflunomide. J Immunol 191(10):4969–4978. https://doi.org/10.4049/jimmunol.1300832 CrossRefPubMed

16.

Duan X-W, Zhang X-L, Mao S-Y, Shang J-J, Shi X-D (2015) Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol 34(9):1513–1519. https://doi.org/10.1007/s10067-015-2999-6 CrossRefPubMed

17.

Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K, Iguratimod-Clinical Study Group (2014) Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 24(3):410–418. https://doi.org/10.3109/14397595.2013.843756 CrossRefPubMed

18.

Yan Q, Du F, Huang X et al (2014) Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PLoS One 9(10):e108273. https://doi.org/10.1371/journal.pone.0108273 CrossRefPubMedPubMedCentral

19.

Zhang P, Gong Y, Liu Z, Liu Y, Lin W, Li J, Wang M, Liu X, Fei Y, Chen H, Peng L, Li J, Zhou J, Shi Q, Zhang X, Shen M, Zeng X, Zhang F, Li Y, Zhao Y, Zhang W (2019) Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: a prospective clinical trial. Int J Rheum Dis 22(8):1479–1488. https://doi.org/10.1111/1756-185X.13633 CrossRefPubMedPubMedCentral

20.

Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, Hamano H, Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T, Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima M, Hibi T, Tsubouchi H, Inui K, Ohara H (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22(1):21–30. https://doi.org/10.1007/s10165-011-0571-z CrossRefPubMed

21.

Carruthers MN, Stone JH, Deshpande V, Khosroshahi A (2012) Development of an IgG4-RD responder index. Int J Rheumatol 2012:1–7. https://doi.org/10.1155/2012/259408 CrossRef

22.

Yunyun F, Yu C, Panpan Z, Hua C, di W, Lidan Z, Linyi P, Li W, Qingjun W, Xuan Z, Yan Z, Xiaofeng Z, Fengchun Z, Wen Z (2017) Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep 7(1):6195. https://doi.org/10.1038/s41598-017-06520-5 CrossRefPubMedPubMedCentral

23.

Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, Uchida K, Okazaki K, Ito T, Kawa S, Yamada K, Kawano M, Hirata S, Tanaka Y, Moriyama M, Nakamura S, Kamisawa T, Matsui S, Tsuboi H, Sumida T, Shibata M, Goto H, Sato Y, Yoshino T, Mimori T (2018) Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep 8(1):1–8. https://doi.org/10.1038/s41598-018-28405-x CrossRef

24.

Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74(6):1171–1177. https://doi.org/10.1136/annrheumdis-2014-206605 CrossRefPubMed

25.

Stone JH (2016) IgG4-related disease: pathophysiologic insights drive emerging treatment approaches. Clin Exp Rheumatol 34(4 Suppl 98):66–68PubMed

26.

Ebbo M, Grados A, Samson M, Groh M, Loundou A, Rigolet A, Terrier B, Guillaud C, Carra-Dallière C, Renou F, Pozdzik A, Labauge P, Palat S, Berthelot JM, Pennaforte JL, Wynckel A, Lebas C, le Gouellec N, Quémeneur T, Dahan K, Carbonnel F, Leroux G, Perlat A, Mathian A, Cacoub P, Hachulla E, Costedoat-Chalumeau N, Harlé JR, Schleinitz N (2017) Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One 12(9):e0183844. https://doi.org/10.1371/journal.pone.0183844 CrossRefPubMedPubMedCentral

27.

Lin W, Zhang P, Chen H, Chen Y, Yang H, Zheng W, Zhang X, Zhang F, Zhang W, Lipsky PE (2017) Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease. Arthritis Res Ther 19(1):25. https://doi.org/10.1186/s13075-017-1231-2 CrossRefPubMedPubMedCentral

Titel: Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease
verfasst von: Yanying Liu
Yuxin Zhang
Wenjie Bian
Jiangnan Fu
Xing Sun
Da Chen
Jiali Chen
Xiaozhen Zhao
Yingni Li
Wen Zhang
Zhanguo Li
Publikationsdatum: 01.02.2020
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 2/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04880-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease

Abstract

Objective

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Leptin as an open secret in the physiopathology of rheumatic diseases

Late-onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile- and adult-onset patients—a multicenter retrospective cohort

Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching

Comment on “Impact of TNF-Α inhibitor on lipid profile and atherogenic index of plasma in axial spondyloarthritis: 2-year follow-up data from the catholic axial spondyloarthritis cohort (CASCO)”

JAK2 and PTPRC mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus

Association between cumulative serum urate and development of diabetes type II: the Kailuan Study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin